company background image
BIOT

BiotageOM:BIOT Stock Report

Last Price

kr184.90

Market Cap

kr12.2b

7D

-15.6%

1Y

25.9%

Updated

19 Jan, 2022

Data

Company Financials +
BIOT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends3/6

BIOT Stock Overview

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications.

Rewards

Earnings are forecast to grow 14.36% per year

Earnings have grown 11.7% per year over the past 5 years

Risk Analysis

No risks detected for BIOT from our risk checks.

Biotage Competitors

Bio-Techne

NasdaqGS:TECH

US$14.9b

Price History & Performance

Summary of all time highs, changes and price drops for Biotage
Historical stock prices
Current Share Pricekr184.90
52 Week Highkr295.60
52 Week Lowkr137.10
Beta0.74
1 Month Change-25.68%
3 Month Change-29.86%
1 Year Change25.87%
3 Year Change59.67%
5 Year Change298.49%
Change since IPO81.27%

Recent News & Updates

Dec 10
Is Biotage (STO:BIOT) A Risky Investment?

Is Biotage (STO:BIOT) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Nov 03
Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?

Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Aug 17
Biotage (STO:BIOT) Has A Rock Solid Balance Sheet

Biotage (STO:BIOT) Has A Rock Solid Balance Sheet

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Jul 24
Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?

Is Now The Time To Put Biotage (STO:BIOT) On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

BIOTSE Life SciencesSE Market
7D-15.6%-8.6%-4.2%
1Y25.9%31.5%17.2%

Return vs Industry: BIOT underperformed the Swedish Life Sciences industry which returned 31.6% over the past year.

Return vs Market: BIOT exceeded the Swedish Market which returned 17.8% over the past year.

Price Volatility

Is BIOT's price volatile compared to industry and market?
BIOT volatility
BIOT Average Weekly Movement5.7%
Life Sciences Industry Average Movement9.3%
Market Average Movement6.9%
10% most volatile stocks in SE Market11.7%
10% least volatile stocks in SE Market3.9%

Stable Share Price: BIOT is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BIOT's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1969478Tomas Blomquisthttps://www.biotage.com

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.

Biotage Fundamentals Summary

How do Biotage's earnings and revenue compare to its market cap?
BIOT fundamental statistics
Market Capkr12.20b
Earnings (TTM)kr203.33m
Revenue (TTM)kr1.19b

60.0x

P/E Ratio

10.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIOT income statement (TTM)
Revenuekr1.19b
Cost of Revenuekr466.55m
Gross Profitkr721.73m
Expenseskr518.40m
Earningskr203.33m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 11, 2022

Earnings per share (EPS)3.08
Gross Margin60.74%
Net Profit Margin17.11%
Debt/Equity Ratio4.3%

How did BIOT perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

48%

Payout Ratio

Valuation

Is Biotage undervalued compared to its fair value and its price relative to the market?

60x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIOT (SEK184.9) is trading above our estimate of fair value (SEK183.46)

Significantly Below Fair Value: BIOT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIOT is poor value based on its PE Ratio (60x) compared to the Swedish Life Sciences industry average (46x).

PE vs Market: BIOT is poor value based on its PE Ratio (60x) compared to the Swedish market (22.6x).


Price to Earnings Growth Ratio

PEG Ratio: BIOT is poor value based on its PEG Ratio (4.2x)


Price to Book Ratio

PB vs Industry: BIOT is overvalued based on its PB Ratio (11.2x) compared to the SE Life Sciences industry average (3.6x).


Future Growth

How is Biotage forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

14.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOT's forecast earnings growth (14.4% per year) is above the savings rate (0.3%).

Earnings vs Market: BIOT's earnings (14.4% per year) are forecast to grow faster than the Swedish market (4.3% per year).

High Growth Earnings: BIOT's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIOT's revenue (10.9% per year) is forecast to grow faster than the Swedish market (5.1% per year).

High Growth Revenue: BIOT's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BIOT's Return on Equity is forecast to be low in 3 years time (19.4%).


Past Performance

How has Biotage performed over the past 5 years?

11.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BIOT has high quality earnings.

Growing Profit Margin: BIOT's current net profit margins (17.1%) are higher than last year (13.8%).


Past Earnings Growth Analysis

Earnings Trend: BIOT's earnings have grown by 11.7% per year over the past 5 years.

Accelerating Growth: BIOT's earnings growth over the past year (36%) exceeds its 5-year average (11.7% per year).

Earnings vs Industry: BIOT earnings growth over the past year (36%) underperformed the Life Sciences industry 68.7%.


Return on Equity

High ROE: BIOT's Return on Equity (18.7%) is considered low.


Financial Health

How is Biotage's financial position?


Financial Position Analysis

Short Term Liabilities: BIOT's short term assets (SEK784.0M) exceed its short term liabilities (SEK289.0M).

Long Term Liabilities: BIOT's short term assets (SEK784.0M) exceed its long term liabilities (SEK124.0M).


Debt to Equity History and Analysis

Debt Level: BIOT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BIOT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BIOT's debt is well covered by operating cash flow (715%).

Interest Coverage: BIOT's interest payments on its debt are well covered by EBIT (9.2x coverage).


Balance Sheet


Dividend

What is Biotage current dividend yield, its reliability and sustainability?

0.81%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BIOT's dividend (0.81%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (0.98%).

High Dividend: BIOT's dividend (0.81%) is low compared to the top 25% of dividend payers in the Swedish market (3.37%).


Stability and Growth of Payments

Stable Dividend: BIOT's dividend payments have been volatile in the past 10 years.

Growing Dividend: BIOT's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (48.1%), BIOT's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BIOT's dividends in 3 years are forecast to be well covered by earnings (34.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Tomas Blomquist (51 yo)

2.17yrs

Tenure

kr4,746,594

Compensation

Mr. Tomas Blomquist has been CEO and President of Biotage AB since November 6, 2019. Mr. Blomquist serves as Independent Director at Nolato AB (publ) since May 4, 2021. Mr. Blomquist served as the Chief Op...


CEO Compensation Analysis

Compensation vs Market: Tomas's total compensation ($USD521.79K) is below average for companies of similar size in the Swedish market ($USD756.57K).

Compensation vs Earnings: Tomas's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: BIOT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: BIOT's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biotage AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Biotage AB (publ)
  • Ticker: BIOT
  • Exchange: OM
  • Founded: 1969
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr12.200b
  • Shares outstanding: 65.98m
  • Website: https://www.biotage.com

Number of Employees


Location

  • Biotage AB (publ)
  • Box 8
  • Uppsala
  • Uppsala County
  • 751 03
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 21:13
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.